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GT>GC 5' splice site variants have been frequently reported to cause human genetic disease. 
However, although we have demonstrated that GT>GC variants in human disease genes may 
not invariably be pathogenic, none of the currently available splicing prediction tools appear 
to be capable of reliably distinguishing those GT>GC variants that generate wild-type 
transcripts from those that do not. Recently, SpliceAI, a novel deep residual neural network 
tool, has been developed for splicing prediction. Methodologically distinct from previous 
approaches that either rely on human-engineered features and/or which focus on short 
nucleotide windows adjoining exon-intron boundaries, SpliceAI assesses splicing 
determinants by evaluating 10,000 nucleotides of flanking contextual sequence to predict the 
functional role in splicing of each position in the pre-mRNA transcript. Herein, we evaluated 
the performance of SpliceAI in the context of three datasets of GT>GC variants, all of which 
had been characterized functionally in terms of their impact on mRNA splicing. Comparison 
of the SpliceAI-predicted and experimentally obtained functional impact assessments of the 
analyzed GT>GC variants revealed that although SpliceAI performed rather better than other 
prediction tools, it was still far from perfect. Our findings highlight the challenges that we still 





Technological advances in DNA sequencing have made whole exome sequencing and even 
whole genome sequencing increasingly practicable, especially in the clinical setting. 
However, our ability to accurately interpret the clinical relevance of genetic variants, 
particularly those that are rare or even private, has so far been quite limited; this represents a 
rate-limiting step in realizing the full potential of precision medicine (Lappalainen et al., 
2019; Shendure et al., 2019). Functional analysis performed in a well-validated assay should 
provide the strongest possible basis for variant classification (Richards et al., 2015; Starita et 
al., 2017) but this is often not feasible in practice for certain types of variant. Many 
computational algorithms have been developed with the aim of predicting the functional 
effects of different types of genetic variant but none of them meets the exacting standards 
required in the clinic. This is particularly true for splice-altering variants outside the obligate 
GT and AG splice‐site dinucleotides because (i) splice-altering variants can occur virtually 
anywhere within a gene’s coding or intronic sequences (Anna and Monika, 2018; Cooper et 
al., 2009; Scotti and Swanson, 2016; Vaz-Drago et al., 2017) and (ii) splicing is a highly 
regulated process, involving a complex interaction between cis-elements and trans-acting 
factors (Baeza-Centurion et al., 2019; Fu and Ares, 2014; Scotti and Swanson, 2016; Shi, 
2017; Wang and Burge, 2008). 
Even for variants that occur within the supposedly obligate splice‐site dinucleotides, we 
may still encounter problems of interpretation. For example, variants affecting the 5' splice 
site GT dinucleotide, which have been frequently reported to cause human genetic disease 
(Stenson et al., 2017), are routinely scored as pathogenic splicing mutations and are usually 
considered to be fully penetrant (Jaganathan et al., 2019; Mount et al., 2019). However, we 
have recently provided evidence to suggest that 5' splice site GT>GC variants (henceforth 
simply termed GT>GC variants or alternatively +2T>C variants) in human disease genes may 
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not invariably be pathogenic (Lin et al., 2019b). Specifically, combining data derived from a 
meta-analysis of 45 human disease-causing GT>GC variants and a cell culture-based Full-
Length Gene Splicing Assay (FLGSA) of 103 GT>GC substitutions, we estimated that ~15-
18% of GT>GC variants generate between 1 and 84% wild-type transcripts (Lin et al., 
2019b). During this analysis, we found that none of the four most popular splicing prediction 
tools, namely SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer (all included 
within Alamut® Visual; https://www.interactive-biosoftware.com/), were capable of reliably 
distinguishing those GT>GC variants that generated wild-type transcripts from those that did 
not (Lin et al., 2019b); for all variants tested, SpliceSiteFinder‐like tended to predict a slightly 
reduced score whilst the other three invariably failed to yield any score. The root of this 
problem is twofold: Firstly, these splicing prediction tools (in common with many others) 
focus exclusively on short local DNA sequence motifs and secondly, GC is used instead of 
GT as the wild-type 5’ splice site dinucleotide in ~1% of U2 type introns in the human 
genome (Burset et al., 2000; Parada et al., 2014). It follows that both GT>GC variants that 
generate wild-type transcripts and those that do not, could in principle occur within identical 
local sequence tracts as far as the conventional 9-bp 5' splice site consensus sequence, 
comprising the last three bases of the preceding exon and the first six bases of the affected 
intron (the corresponding nucleotide positions are denoted -3_-1/+1_+6), is concerned (Lin et 
al., 2019b).  
Recently, SpliceAI, a novel deep residual neural network tool, has been developed for 
splicing prediction (Jaganathan et al., 2019). Methodologically distinct from previous 
approaches that have either relied on human-engineered features and/or focused on short 
nucleotide windows adjoining exon-intron boundaries, SpliceAI learns splicing determinants 
directly from the primary sequence by evaluating 10,000 nucleotides of the flanking sequence 
context to predict the role in splicing of each position in the pre-mRNA transcript. Jaganathan 
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et al. (2019) showed that SpliceAI achieved a top-k accuracy of 95% for pre-mRNA 
transcripts of protein-coding genes and 84% for long intergenic noncoding RNAs (lincRNAs) 
in the test dataset. [Top-k accuracy is defined as the fraction of correctly predicted splice sites 
at the threshold where the number of predicted sites is equal to the actual number of splice 
sites present in the test dataset] The accuracy and reliability of SpliceAI was evidenced by (i) 
the observation that synonymous and intronic variants with predicted splice-altering impact 
were found to be depleted in the human population, (ii) the fact that 75% of these 
synonymous and intronic mutations were validated by RNA-seq and (iii) the finding that de 
novo cryptic splice variants were enriched in patients with neurodevelopmental disorders 
(Jaganathan et al., 2019). Herein, we sought to ascertain whether SpliceAI is capable of 
accurately distinguishing GT>GC variants that generate wild-type transcripts from those that 
do not. 
 
2. MATERIALS AND METHODS 
2.1. Source of GT>GC variants 
Three datasets of GT>GC variants, all of which have been characterized functionally in terms 
of their impact on splicing, were employed in this study. The first two datasets correspond to 
our previously described “in vivo” dataset of 45 disease-causing GT>GC variants and the “in 
vitro” dataset of 103 GT>GC substitutions (Lin et al., 2019b). The third dataset comprised 12 
GT>GC variants from the BRCA1 gene, which were extracted from a recent study that 
prospectively analyzed the functional impact of over 4000 BRCA1 variants by means of 
saturation genome editing (Findlay et al., 2018).  
In the context of the first dataset (Supplementary Table S1), the precise level of the variant 
allele-derived wild-type transcripts was available for four of the seven disease-causing 
GT>GC variants that generated wild-type transcripts in the corresponding original 
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publications (Table 1). For the three remaining variants (i.e., CAV3 c.114+2T>C in (Muller et 
al., 2006); PLP1 c.696+2T>C in (Aoyagi et al., 1999) and SPINK1 c.194+2T>C in (Kume et 
al., 2006)), it is apparent from RT-PCR gel photographs in the original publications that all 
three were associated with the generation of both wild-type and aberrantly spliced transcripts. 
We employed ImageJ (https://imagej.net) to provide approximate estimates of the levels of 
the variant allele-derived wild-transcripts for each of the three variants (Table 1).  
 
2.2. Variant description and nomenclature 
Variant description and nomenclature were in line with our previous publication (Lin et al., 
2019b). First, we used the term ‘variants’ to describe naturally occurring disease-causing 
events and ‘substitutions’ to denote artificially engineered events. Second, 5’ splice site 
GT>GC, GT>GA and GT>GG variants or substitutions were used synonymously with 
+2T>C, +2T>A and +2T>G variants or substitutions, respectively. Third, disease-causing 
variants were named in accordance with Human Genome Variation Society (HGVS) 
recommendations (den Dunnen et al., 2016) whilst the traditional IVS (InterVening Sequence; 
i.e., an intron) nomenclature was used for the engineered substitutions. Finally, hg38 positions 
(https://genome.ucsc.edu/) for all variants or substitutions under study are systematically 
provided in the various tables.  
 
2.3. SpliceAI prediction 
GT>GC variants or substitutions as well as their corresponding GT>GA and GT>GG 
counterparts were processed (during October 2019) using the default settings of SpliceAI 
version 1.2.1,with a custom gene annotation file containing NCBI reference sequence 
transcript start and end coordinates. Default settings, and instruction for use of custom 




2.4. Performance testing 
Two statistical tests, a Matthews correlation coefficient (MCC) and a Receiver operating 
characteristic (ROC) curve, were carried out on the dataset 2 substitutions assessed by 
SpliceAI. MCC test is a correlation coefficient between the observed and predicted binary 
classifications. For a perfect prediction, the coefficient is +1; a coefficient of 0 is no better 
than random, and no correlation between observed and predicted yields -1 (Matthews, 1975). 
A ROC curve illustrates the diagnostic specificity and sensitivity of a binary classifier system 
as its discrimination threshold is varied; this enables the selection of an optimum threshold 
value. To assess the difference between the diagonal and the ROC curve obtained, the area 
under the ROC curve is measured (AUC). An AUC of 0.5 would be a random prediction 
whilst a perfect predictor would score 1. ROC analysis was carried out using the R-based web 
tool easyROC (Goksuluk et al., 2016). 
For the MCC test, a contingency table was derived from dataset 2 (Supplementary Table 
S2) where a true positive is defined as a predicted splice altering substitution for which 
FLGSA produced no transcript and a true negative is a substitution not predicted to alter 
splicing and for which FLGSA produces transcript. 
 
2.5. Functional analysis of two GT-affecting variants 
The functional impact of two newly engineered GT-affecting variants in the HESX1 gene 
were analyzed by means of the cell culture-based FLGSA method as previously described 
(Lin et al., 2019b).  
 
3. RESULTS AND DISCUSSION 
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3.1. Accuracy and reliability of the experimentally obtained functional assessment of the 
GC>GT variants analyzed 
We employed SpliceAI to make predictions as to the splicing consequences of GT>GC 
variants from three distinct datasets. Since the experimentally ascertained functional impact of 
the GT>GC variants analyzed was used as the starting point for our analysis, their accuracy 
and reliability were of critical importance. Regarding the first dataset of known pathogenic 
variants (Supplementary Table S1), several points are worth highlighting. First, all 45 disease-
causing variants were either homozygotes, hemizygotes or compound heterozygotes, a 
prerequisite for determining the presence or absence of the variant allele-derived normal 
transcripts. Second, for each variant, patient-derived tissue or cells (pathologically relevant in 
about half of the cases) had been used to perform the RT-PCR analysis that had unequivocally 
demonstrated the presence or absence of variant allele-derived wild-type transcripts in the 
corresponding original publication. Third, the levels of the variant allele-derived wild-type 
transcripts in the seven disease-causing GT>GC variants that generated wild-type transcripts 
were very low (≤15% of normal; Table 1), potentially explicable by the ascertainment bias 
inherent to all disease-causing variants. Nonetheless, all seven of these variants were noted to 
be associated with a milder clinical phenotype than would have been expected from a 
functionally null variant (Lin et al., 2019b), consistent with other findings that even the 
retention of a small fraction of normal gene function can significantly impact the clinical 
phenotype (Den Uijl et al., 2011; Ramalho et al., 2002; Raraigh et al., 2018; Scalet et al., 
2019). 
In the case of the second dataset (Supplementary Table S2), the functional effects of all 
103 engineered GT>GC substitutions (from 30 different genes) were analyzed by Full-Length 
Gene Splicing Assay (FLGSA) in transfected HEK293T cells (Lin et al., 2019b), with all 19 
substitutions that generated some wild-type transcripts being listed in Table 2. By comparison 
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to the commonly used minigene splicing assay, FLGSA preserves better the natural genomic 
sequence context of the studied variants (Wu et al., 2017; Zou et al., 2016). The accuracy and 
reliability of the FLGSA-derived data can be inferred from the following three lines of 
evidence. First, 10 GT>GC substitutions that generated wild-type transcripts and 10 GT>GC 
substitutions that did not generate wild-type transcripts in transfected HEK293T cells were 
further analyzed in transfected HeLa cells using FLGSA, yielding entirely consistent findings 
in terms of whether or not wild-type transcripts were generated (Lin et al., 2019b). Second, 
HESX1 c.357+2T>C and SPINK1 c.194+2T>C were the only variants common to both the 
first and second datasets. The functional effects of these two variants in vivo — HESX1 
c.357+2T>C generated no wild-type transcripts whereas SPINK1 c.194+2T>C generated 
some wild-type transcripts (Supplementary Table S1) — were faithfully replicated in FLGSA 
(Supplementary Table S2). Third, a GT>GC variant that was not present in either dataset, 
HBB c.315+2T>C, had been reported to be associated with a milder hematological phenotype 
and it was suggested that it might have a limited impact on splicing (Frischknecht et al., 
2009). Using FLGSA performed in HEK293T cells, we found that it generated a low level of 
wild-type transcripts (Lin et al., 2019b). Importantly, the orthologous variant of HBB 
c.315+2T>C in the rabbit Hbb gene has also been found to be capable of generating wild-type 
transcripts in two experimental model systems, namely in vitro transcription of Hbb RNA in a 
HeLa cell nuclear extract and transient expression of the full-length Hbb gene in HeLa cells 
(Aebi et al., 1986; Aebi et al., 1987). These notwithstanding, tissue-or cell-specific factors 
have on some occasions impacted splicing (Jaganathan et al., 2019; Pineda and Bradley, 
2018), an issue that was not extensively addressed in our previous study (Lin et al., 2019b). 
The bottom line here is that (i) the 30 genes used for FLGSA analysis were selected using a 
procedure that did not take into consideration the gene’s function or expression, (ii) all 30 
genes underwent normal splicing in the context of their reference mRNA sequences as 
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specified in Supplementary Table S2 and (iii) the generation (or not) of wild-type transcripts 
from the engineered GC allele was observed under the same experimental conditions as for 
the wild-type GT allele (Lin et al., 2019b). 
The third dataset was obtained courtesy of aperusal of the literature (Table 3). Recently, 
the functional impact of all possible single nucleotide substitutions within 13 exons and 
adjacent intronic sequences of the 23-exon BRCA1 gene (NM_007294.3) have been 
prospectively analyzed by means of saturation genome editing (Findlay et al., 2018). Taking 
advantage of the ssentiality of BRCA1 in the human near-haploid cell line HAP1 (Blomen et 
al., 2015), Findlay and colleagues used cell viability as a proxy indicator for the functional 
consequences of the analyzed substitutions. It should be noted that the functional 
consequences of all tested substitutions were actually evaluated in their natural genomic 
sequence contexts. Of the ~4000 BRCA1 single nucleotide substitutions analyzed, 12 were 
GT>GC substitutions. Of these 12 GT>GC substitutions, one was classified as “functional”, 
two were classified as “intermediate” and the remaining nine were classified as “non-
functional” (Table 3). Whereas “functional” and “intermediate” were interpreted as having 
generated wild-type transcripts, “non-functional” was interpreted as having not generated any 
wild-type transcripts (Lin et al., 2019a). As such, 25% (n = 3) of these 12 BRCA1 GT>GC 
substitutions generated wild-type transcripts, a proportion largely consistent with our 
estimated 15-18% rate. Moreover, the BRCA1 GT>GC variant in intron 18 was shown to be 
“functional”, providing further support for our contention that GT>GC variants in human 
disease genes may not invariably be pathogenic (Lin et al., 2019b). 
Taken together, the experimentally obtained functional assessments of the included 
GC>GT variants or substitutions were considered to be of high quality and appropriate for the 




3.2. Selection and interpretation of SpliceAI Delta scores for analysis 
We processed GT>GC variants using the default settings of SpliceAI as detailed in 
https://pypi.org/project/spliceai/. SpliceAI provides Delta scores (ranging from 0 to 1) for 
each variant, thereby providing a measure of their probability of altering splicing in terms of 
either splice donor gain, splice donor loss, splice acceptor gain, and splice acceptor loss. 
SpliceAI also provides Delta position that conveys information specifying the location where 
splicing differs from normal relative to the position of the associated variant. Since the 
GT>GC variants or substitutions under study invariably affected the +2 position of the 
canonical 5' splice site GT dinucleotides (in the context of the specified mRNA reference 
sequence), we focused our analysis exclusively on the Delta scores of donor loss although 
other scores may provide clues as to the nature of the resulting aberrantly spliced transcripts 
of splice-altering variants. Thus, only the SpliceAI-predicted Delta scores of donor loss for 
the studied GT>GC variants or substitutions are provided in Supplementary Tables S1 and S2 
as well as in Tables 1-3.  
In the original work of Jaganathan and colleagues, Delta scores of 0.2, 0.5 and 0.8 were 
used as cutoff values to define variants as “high recall/likely pathogenic”, 
“recommended/pathogenic” and “high precision/pathogenic”, (Matt: you deleted the pervious 
words and inserted the following words in brackets. But this is no longer a sentence. Could 
you please rewrite?) [Used as statistical terms for the data as a whole rather than a measure of 
variant pathogenicity]respectively (Jaganathan et al., 2019). In this regard, it is important to 
note two points in the context of GT>GC variants. The previously studied GT>GC events 
generated maximally 84% wild-type transcripts as compared to their wild-type GT allele 
counterparts (Lin et al., 2019b). In other words, all these variants were associated minimally 
with a 16% functional loss. Therefore, strictly speaking, all these previously studied GT>GC 
events can be defined as splice-altering. On the other hand, in those cases of GT>GC events 
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that generated wild-type transcripts, the level of wild-type transcript varied from 1-84% (Lin 
et al., 2019b). Intuitively, whether or not a GT>GC variant capable of generating wild-type 
transcripts is pathogenic is likely to depend at least in part upon the level of the generated 
wild-type transcripts. Taking these points into consideration, we shall use the SpliceAI Delta 
score of donor loss as a proxy indicator of the probability of a given GT>GC variant being 
able to generate wild-type transcripts; variants with a Delta score above a certain cutoff value 
will be considered not to be capable of generating wild-type transcripts whereas variants with 
a Delta score below the cutoff value will beconsidered as being capable of generating wild-
type transcripts. 
 
3.3. Encouraging findings from a quick survey of the three datasets of GT>GC variants 
As mentioned in the Introduction, none of the four most popular splicing prediction tools, 
SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer, were found to be able to 
distinguish those GT>GC variants that generated wild-type transcripts from those that did not 
(Lin et al., 2019b). As described below, a quick survey of SpliceAI-predicted scores yielded 
encouraging results across all three datasets of GT>GC variants. 
First, in the context of dataset 1, the level of variant allele-derived wild-type transcripts 
associated with the seven disease-causing GT>GC variants was at most 15% of normal (Table 
1). Although this low level increase in the generation of wild-type transcripts may make 
prediction a daunting task, it is interesting to see that the two lowest Delta scores of donor 
loss, 0.35 and 0.63, were observed in association with the two variants that generated ~10% 
wild-type transcripts (Supplementary Table S1; Table 1). The score of 0.35 was observed for 
the SPINK1 c.194+2T>C variant, for which the RT-PCR analysis was performed using gastric 
tissue from a homozygous patient with chronic pancreatitis (Kume et al., 2006). Although 
stomach is not known to be clinically affected in chronic pancreatitis, the expression data 
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were considered to be highly reliable for two reasons. Firstly, the in vivo expression data was 
confirmed by FLGSA performed in both HEK293T and HeLa cells (Lin et al., 2019b). 
Secondly, had the SPINK1 c.194+2T>C variant in question caused a complete functional loss 
of the affected allele, the homozygotes should have developed severe infantile isolated 
exocrine pancreatic insufficiency instead of chronic pancreatitis (Venet et al., 2017). The 
score of 0.63 was observed for the DMD c.8027+2T>C variant, for which the detection of 
wild-type transcripts was based upon RT-PCR analysis of disease-affected muscle tissue from 
a hemizygous carrier with Becker muscular dystrophy (Bartolo et al., 1996).  
As for the second dataset (Supplementary Table S2), the four lowest Delta scores of donor 
loss (i.e., 0, 0.03, 0.05 and 0.08) were all found in substitutions that generated wild-type 
transcripts; and 63% (n = 12) of the 19 substitutions that generated some wild-type transcripts 
had a Delta score of <0.80 (Table 2). As for the third dataset, the lowest Delta score, 0.53, 
was observed in association with the only “functional” BRCA1 IVS18+2T>C variant (Table 
3).  
 
3.4. Statistical comparison of experimentally obtained functional data with SpliceAI 
predictions for the 103 engineered GT>GC splice variants (dataset 2)
Dataset 2 comprised 19 substitutions that generated wild-type transcripts and 84 substitutions 
that generated no wild-type transcripts. We thus performed two statistical tests, a Receiver 
operating characteristic (ROC) curve and a Matthews correlation coefficient (MCC), on the 
103 substitutions assessed by SpliceAI (Supplementary Table S2) with a view both to 
identifying an optimum threshold value and to assessing the correlation between the FLGSA 
assay results and the SpliceAI predictions. 
Based on an ROC analysis of 103 variants from dataset 2 (Supplementary Table S2), an 
optimum threshold point of 0.85 was provided - similar to the threshold of 0.80, 
21 
 
recommended by SpliceAI for high precision results. A contingency table was constructed 
(Supplementary Table S3) to calculate values for the false positive rate, specificity, 
sensitivity, accuracy and the Matthews correlation coefficient. These are summarized in Table 
4, along with the AUC result obtained from the ROC analysis, the curve from which is shown 
in Fig. 1. 
As can be seen from Table 4, the AUC of 0.79 and the MCC score of 0.41 are indicative 
of a good correlation between predicted and actual results. There is also a low false positive 
rate whilst still maintaining a high accuracy and sensitivity. These results show that for 
dataset 2, at a threshold of 0.85, SpliceAI can accurately discriminate between those GT>GC 
substitutions which disrupt splicing and transcript production and those which do not disrupt 
splicing and produce transcript.  
 
3.5. Considerable discrepancy between the predicted and experimentally obtained 
functional impact assessments of GT>GC 5' splice site variants 
Employing 0.85 as the threshold Delta score (donor loss) to define the generation of wild-type 
transcripts, rather variable performance between SpliceAI-predicted and experimentally 
demonstrated functional effects of GT>GC variants were observed across the three datasets: 
33-84% of the variants that generated wild-type transcripts and 67-89% of the variants that 
generated no wild-type transcripts were correctly predicted by SpliceAI (Table 5).  
The poorest performance (43% (3/7) and 33% (1/3)) was observed with datasets 1 and 3 
variants that generated wild-type transcripts (Table 5). In the context of the seven dataset 1 
variants that generated wild-type transcripts (a qualitative property), the relatively poor 
performance of 43% might be related to the fact that the functional impact of these GT>GC 
variants actually manifested as rather small quantitative changes, generating between 1-15% 
normal transcripts (Table 1). This notwithstanding, it should be pointed out that the two 
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disease-causing variants that generated 10-15% wild-type transcripts, CAV3 c.114+2T>C 
(Muller et al., 2006) and CD40LG c.346+2T>C (Seyama et al., 1998), had Delta scores of 
≥0.9 (Table 1); and in each of these two cases, RT-PCR analysis was performed using patient-
derived and pathologically relevant tissue or cells. In short, it remains unclear why some of 
the disease-causing variants that generated comparable levels of wild-type transcripts were 
predicted to have low Delta scores (i.e., DMD c.8027+2T>C and SPINK1 c.194+2T>C) 
whereas others were predicted to have high Delta scores (i.e., CAV3 c.114+2T>C and 
CD40LG c.346+2T>C). In the context of dataset 3 substitutions that generated wild-type 
transcripts, the precise levels of wild-type transcripts generated by the two “intermediate” 
BRCA1 +2T>C substitutions (both had a Delta score of ≥0.93; Table 3) were unknown.  
As for variants that did not generate wild-type transcripts, an excellent correlation rate, 
89%, was observed with the 38 such disease-causing variants. By contrast, the performance in 
datasets 2 and 3 variants was much lower and almost identical (68% and 67%, respectively; 
Table 5). A fundamental difference between dataset 1 variants and the latter two dataset 
substitutions is that all of the former were previously published whilst almost all of the latter 
were prospectively generated. Thus, it is tempting to speculate that for most of the 38 disease-
causing variants that did not generate wild-type transcripts, their functional effects might have 
been ‘seen’ by SpliceAI during training, thereby leading to a higher correlation rate.  
In an attempt to further understand the poor performance of dataset 2 and 3 substitutions 
that did not generate wild-type transcripts, we opted to use the corresponding +2T>A and 
+2T>G substitutions as controls. The underlying premise was that, based upon current 
knowledge, +2T>A and +2T>G variants should completely disrupt normal splicing and 
consequently have high Delta scores in virtually all cases (see also section 3.6). Here it is 
worth mentioning that we previously employed FLGSA to analyze the functional impact of 15 
+2T>A substitutions and 18 +2T>G substitutions, none of which generated any wild-type 
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transcripts (Lin et al., 2019b). We processed all corresponding +2T>A and +2T>G variants by 
means of SpliceAI in the same way as for the +2T>C variants (during October 2019), the 
resulting Delta scores for donor loss being provided in Tables 1-3 and Supplementary Tables 
S1 and S2.  
As shown in Supplementary Table S1, all +2T>A and +2T>G variants corresponding to 
the 45 disease-causing +2T>C variants had very high Delta scores, ranging from 0.92 to 1. By 
contrast, 91% (n = 94) of the +2T>A and +2T>G variants corresponding to the 103 dataset 2 
+2T>C substitutions had a Delta score of ≥0.85 (Supplementary Table S2). In other words, 
nine of the 103 +2T sites were predicted to have a Delta score of <0.85 when substituted by 
either A or G; and in these sites, the Delta scores are often identical for all three possible 
substitutions (Table 6). One possible reason for lower than expected Delta scores is provided 
in (Jaganathan et al., 2019); exons which undergo a substantial degree of alternative splicing, 
defined as being between 10% and 90% exon inclusion averaged across samples, tend 
towards intermediate scores (stated as between 0.35 and 0.8). We therefore explored this 
possibility using the two sites for which all possible substitutions had the lowest Delta scores 
(i.e., 0.59 and 0.3; Table 6) as examples. To this end, alternative transcripts of the genes of 
interest were surveyed via https://www.ncbi.nlm.nih.gov/gene/. 
All three possible single nucleotide substitutions in the RPL11 g.23695910T (IVS5+2T in 
accordance with NM_000975.5) site had an identical Delta score of 0.59. RPL11 has two 
transcripts, the other being NM_001199802.1. Nonetheless, the two transcripts have common 
coding sequences from exons 3-6. Moreover, all three possible single nucleotide substitutions 
in the NM_000975.5-defined RPL11 IVS5+2T site have been previously subjected to 
FLGSA, invariably generating no wild-type transcripts (Lin et al., 2019b). Taken together, in 




All three possible single nucleotide substitutions in the LY6G6F g.31708136T (IVS5+2T 
in accordance with NM_001003693.1) site had a score of 0.3 (Table 6). NM_001003693.1-
defined LY6G6F has sequence from exons 1 to 4 in common with NM_001353334.2-defined 
LY6G6F-LY6G6D, which represents naturally occurring readthrough transcription between 
the neighboring LY6G6F and LY6G6D genes on chromosome 6 (Supplementary Fig. S1). By 
contrast, NM_001003693.1-defined exons 5 and 6 are spliced out in NM_001353334.2-
defined LY6G6F-LY6G6D. It is likely that the use of the “LY6G6F IVS5+2T site” as a splice 
site in one transcript isoform but not in the other underlies the similarly low Delta scores for 
the three above mentioned possible single nucleotide substitutions. However, two points 
should be emphasized here. Firstly, none of the three possible single nucleotide substitutions 
in the context of the NM_001003693.1-defined LY6G6F IVS5+2T site led to the generation 
of wild-type transcripts as evidenced by FLGSA. Whether these substitutions would lead to 
the increased use of NM_001353334.2-defined LY6G6F-LY6G6D remains unclear. Secondly, 
all three possible single nucleotide substitutions, if considered only in the context of 
NM_001353334.2-defined LY6G6F-LY6G6D (Supplementary Fig. S1), may not affect gene 
splicing at all.  
Finally, let us turn our attention to the BRCA1 findings in relation to NM_007294.3 (Table 
3). The lowest Delta score of donor loss in the context of +2T>A and +2T>G variants, 0.65, 
was observed for all three possible SNVs in the BRCA1 IVS4+2T site. The next lowest score, 
0.67, was observed for all three possible SNVs in the BRCA1 IVS5+2T site (Table 3). All six 
of these variants have been analyzed using saturation genome editing and were invariably 
classified as “non-functional” (Jaganathan et al., 2019). Moreover, although BRCA1 has 
multiple transcripts, these two introns are used by all transcripts (Supplementary Fig. S2). 
Therefore, as in the abovementioned RPL11 case, these lower than expected Delta scores 




3.6. Additional findings 
We succeeded in analyzing two additional engineered GT-impacting substitutions in the 
HESX1 gene, IVS2+2T>A (hg38# chr3:57198751A>T) and IVS3+2T>G (hg38# 
chr3:57198389A>C), using the cell culture-based FLGSA method. Interestingly, the 
IVS2+2T>A substitution generated both wild-type and aberrant transcripts whereas 
IVS3+2T>G generated only aberrant transcripts (Fig. 2). Moreover, two of the 12 BRCA1 
+2T>A substitutions, IVS16+2T>A and IVS18+2T>A, were described as being 
“intermediate” (Table 3). Although no disease-causing +2T>A variants have been found to 
generate wild-type transcripts, GA has recently been ranked fourth in terms of its relative 
frequency among the six noncanonical 5’ splice sites identified by genome-wide RNA-seq 
analysis and splicing reporter assays (Erkelenz et al., 2018). However, of the three +2T>A 
substitutions that were experimentally shown to generate some wild-type transcripts, two 
were predicted to have a Delta score of >0.85, namely 0.93 for HESX1 IVS2+2T>A 
(Supplementary Table S2) and 0.98 for BRCA1 IVS18+2T>A (Table 3). The other one, 
BRCA1 IVS16+2T>A, was predicted to have a Delta score of 0.74; but an identical score was 
also predicted for BRCA1 IVS16+2T>C and IVS16+2T>G, both of which were classified as 
“non-functional” (Table 3). In short, SpliceAI appeared not to work as well for the +2T>A 
variants that generated wild-type transcripts as for the +2T>C variants that generated wild-
type transcripts.  
 
4. CONCLUSIONS AND PERSPECTIVES 
In the present study, we attempted to correlate SpliceAI-predicted and experimentally 
obtained functional effects of GT>GC variants in the context of three independent and 
complementary datasets. Employing data from dataset 2 substitutions, we were able to 
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propose a Delta score of donor loss, 0.85, as defining the threshold of whether or not wild-
type transcripts would be generated by GT>GC variants; whereas a score of ≥0.85 defines the 
complete absence of wild-type transcripts, a score of <0.85 defines the generation of at least 
some wild-type transcripts. Subsequent use of this threshold score to correlate SpliceAI-
predicted and experimentally obtained functional effects of the GT>GC variants revealed that 
SpliceAI performed better than the popular prediction tools such as SpliceSiteFinder-like, 
MaxEntScan, NNSPLICE and GeneSplicer. However, a considerable discrepancy still existed 
between SpliceAI-predicted and experimentally obtained functional assessments in relation to 
GT>GC (as well as GT>GA) variants. Indeed, this discrepancy serves to illuminate the 
challenges ahead in accurately identifying all splice-altering variants. A key issue here is that 
the impact of GT>GC (as well as GT>GA) variants that generated wild-type transcripts 
represents a quantitative change that can vary from barely detectable to almost full expression 
of wild-type transcripts, with wild-type transcripts often co-existing with aberrantly spliced 
transcripts. This is also the case for most of the splice-altering variants occurring outside the 
essential splice site dinucleotides, whose effects “are not fully penetrant and a mixture of both 
normal and aberrant splice isoforms are produced” (Jaganathan et al., 2019). Moreover, there 
is also the issue of alternative splicing related to tissue- or cell-specific factors. While it is 
clear that we are still very far acquiring a full understanding of the ‘splicing code’ (Bao et al., 
2019), we are of the opinion that any improvement in the prioritization of splicing variants 
will necessitate the refinement of in silico prediction tools by reference to in vitro functional 
assessment courtesy of the results obtained from well-validated assays such as FLGSA. 
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Figure 1. A receiver operating characteristic (ROC) curve for SpliceAI dataset 2 results, with 




Figure 2. RT-PCR analyses of HEK293T cells transfected with full-length HESX1 gene 
expression constructs carrying respectively the wild-type and four different nucleotide 
substitutions. Wild-type transcripts emanating from the wild-type construct and the construct 
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containing the IVS2+2T>A substitution (confirmed by DNA sequencing) are indicated by 
arrows. IVS2+2T>A (hg38# chr3:57198751A>T) and IVS3+2T>G (hg38# 
chr3:57198389A>C) substitutions were newly analyzed here. IVS1+2T>A and IVS1+2T>G, 
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